MedTrace Logo

To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

NCT06500689 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 366

Last updated 2024-07-15

No results posted yet for this study

Summary

The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Allisartan Isoproxil (240 mg).

Conditions

  • Essential Hypertension

Interventions

DRUG

Allisartan Isoproxil/Sustained-Release Indapamide

Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide. Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide.

DRUG

Allisartan Isoproxil

Double-blind period (Week 1\~Week 12): Allisartan Isoproxil. Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide.

Sponsors & Collaborators

  • Shenzhen Salubris Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jinxiu Lin, MD · The First Affiliated Hospital of Fujian Medical University, Fuzhou 350212, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2023-11-27
Completion
2024-05-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06500689 on ClinicalTrials.gov